Tarsus Pharmaceuticals TARS

$ 48.05 3.56%

Quarterly report 2024-Q3
added 11-13-2024

Tarsus Pharmaceuticals Balance Sheet 2011-2024 | TARS

Annual Balance Sheet Tarsus Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-195 M	-51.5 M	-170 M	-168 M	-57.8 M	-2.36 M	-	-	-	-	-	-	-
Long Term Debt	29.8 M	19.4 M	585 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	398 K	721 K	609 K	282 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	605 K	63.5 M	3.56 M	-	-	-	-	-	-	-
Total Current Liabilities	36.9 M	15.4 M	11.5 M	5.39 M	-	-	-	-	-	-	-	-	-
Total Liabilities	68.5 M	35 M	12.2 M	5.99 M	64.3 M	3.74 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	697 K	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-245 M	-109 M	-46.7 M	-	-6.03 M	-1.36 M	-	-	-	-	-	-	-
Total Assets	265 M	228 M	179 M	172 M	58.3 M	2.39 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	225 M	71.7 M	171 M	168 M	58 M	-	-	-	-	-	-	-	-
Book Value	197 M	193 M	167 M	166 M	-6 M	-1.35 M	-	-	-	-	-	-	-
Total Shareholders Equity	197 M	193 M	167 M	166 M	-6 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Tarsus Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	71.7 M	71.6 M	29.9 M	29.8 M	29.7 M	24.6 M	24.5 M	19.4 M	19.4 M	19.3 M	19.2 M	-	755 K	405 K	456 K	549 K	549 K	549 K	549 K	100 K	100 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	139 M	125 M	74.1 M	68.5 M	54.7 M	41.2 M	37.8 M	35 M	33.8 M	31.3 M	32.3 M	12.2 M	11.3 M	11 M	10.7 M	5.99 M	5.99 M	5.99 M	5.99 M	919 K	919 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	174 K	697 K	1.03 M	1.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-337 M	-314 M	-280 M	-245 M	-203 M	-164 M	-132 M	-109 M	-95.2 M	-72.7 M	-66.9 M	-46.7 M	-31.8 M	-16.1 M	-22.5 M	-32.8 M	-32.8 M	-32.8 M	-32.8 M	-6.03 M	-6.03 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	376 M	377 M	349 M	265 M	268 M	189 M	211 M	228 M	236 M	253 M	181 M	179 M	190 M	203 M	194 M	172 M	172 M	172 M	172 M	58.3 M	58.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	176 M	181 M	194 M	225 M	227 M	107 M	66 M	71.7 M	169 M	245 M	175 M	171 M	184 M	177 M	156 M	168 M	168 M	168 M	168 M	58 M	58 M	-	-	2.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	237 M	252 M	275 M	197 M	214 M	148 M	173 M	193 M	203 M	222 M	149 M	167 M	179 M	192 M	183 M	166 M	166 M	166 M	166 M	57.4 M	57.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	237 M	252 M	275 M	197 M	214 M	148 M	173 M	193 M	203 M	222 M	149 M	167 M	179 M	192 M	183 M	166 M	166 M	166 M	166 M	-6 M	-6 M	-3.92 M	-3.1 M	-1.35 M	-	-	-	-44 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency